When the concentration of each biomarker was assessed in the group of patients with SS, all showed statistically significant differences with respect to the CTs, with the changes indicating an upregulation of S100A6 and MMP-9, and a downregulation of CST4 in SS patients (Table 2). Here, MMP9 is linked to synovial sarcoma.